Pharmacokinetic properties of fentanyl effervescent buccal tablets: A phase I, open-label, crossover study of single-dose 100, 200, 400, and 800 μg in healthy adult volunteers*

https://doi.org/10.1016/j.clinthera.2006.05.015Get rights and content

Abstract

Background: The fentanyl effervescent buccal tablet (FEBT) is designed to enhance the rate and extent of the absorption of fentanyl, an opioid, through the buccal mucosa.

Objectives: The purposes of this study were to assess the dose proportionality of FEBT in healthy volunteers over the potential therapeutic dose range (100–800 μg) and characterize the pharmacokinetic (PK) profile of 4 doses (100, 200, 400, and 800 μg) of FEBT.

Methods: This Phase I, randomized, open-label, 4-period crossover study was conducted at Radiant Research, Honolulu, Hawaii. Healthy adult volunteers with intolerance to opioids were randomly assigned to receive 1 of 4 single-dose sequences of FEBT: 100, 200, 400, and 800 μg (selected to encompass the anticipated therapeutic dose range), with each successive administration separated by a washout period of ≥7 days. Naltrexone hydrochloride (50-mg tablet) was administered-15 and 3 hours before and 9 hours after FEBT administration to block opioid receptor-mediated effects of fentanyl. Plasma fentanyl concentrations were measured from venous samples obtained over 72 hours after FEBT administration. Early fentanyl exposure was assessed using AUC from time 0 to 0.75 hour (the median Tmax of the reference dose [100 μg]) (AUC0-Tmax′). Adverse events (AEs) were monitored and recorded throughout the study by medically qualified personnel.

Results: Thirty-two subjects (26 men, 6 women; mean [SD] age, 29.3 [7.2] years [range, 19–44 years]; mean [SD] weight, 74.7 [10.7] kg) were enrolled. Median T was between 35 and 45 minutes after FEBT administration. AUC0−∞ and Cmax increased approximately linearly with increasing doses of FEBT. Mean plasma fentanyl concentrations decreased from Cmax in a biexponential manner at the 100- and 200-μg doses and decreased in a triexponential manner at the 800-μg dose. Despite the triexponential decrease in the mean profile observed with the 400-μg dose, a biexponential decrease was observed in approximately half of the individual profiles. AUC0−Tmax′ ranged from 0.09 ng · h/mL with the 100-μg dose to 0.52 ng · h/mL with the 800-μg dose. The most commonly reported AEs in the 100-, 200-, 400-, and 800-μg dose groups were as follows: application-site erythema, 3, 3, 4, and 3 subjects, respectively; nausea, 3, 2, 5, and 4 subjects; somnolence, 3, 2, 3, and 2 subjects; and headache, 3, 2, 1, and 4 subjects. None of the AEs were serious.

Conclusions: In this study of the dose proportionality of FEBT in healthy volunteers, the PK profile of FEBT was characterized by a high early systemic exposure of fentanyl (0.09–0.52 ng · h/mL). Dose-dependent parameters (Cmax and AUC) increased in an approximately dose-proportional manner from 100 to 800 μg FEBT.

References (14)

There are more references available in the full text version of this article.

Cited by (45)

  • Single-Dose Pharmacokinetics of Fentanyl Sublingual Spray and Oral Transmucosal Fentanyl Citrate in Healthy Volunteers: A Randomized Crossover Study

    2013, Clinical Therapeutics
    Citation Excerpt :

    All the reported adverse events were mild, and none occurred in >2 participants in any treatment period. There were no major differences in adverse event profiles between treatments, which were comparable with those previously reported in healthy volunteers receiving transmucosal fentanyl preparations accompanied by naltrexone.27–30 This study found that FSS provided faster drug absorption and had greater bioavailability than OTFC.

  • Fentanyl (transmucosal)

    2012, Journal of Pain and Symptom Management
    Citation Excerpt :

    About two-thirds of any swallowed fentanyl will be eliminated by intestinal or hepatic first-pass metabolism. Nonetheless, significant amounts of swallowed fentanyl are absorbed, e.g., about 25%, 20% and 15% of the systemically available Actiq®, Onsolis® and Fentora®, respectively, is via GI absorption.6,8,15 The effects of the GI absorption on the plasma concentration of fentanyl include producing a ‘double peak,’ maintaining high levels for longer (e.g., >2 h) and contributing to the wide range in Tmax.5

  • Pharmacokinetics of Fentanyl Buccal Tablet: A Pooled Analysis and Review

    2012, Pain Practice
    Citation Excerpt :

    Thus, this highlights the finding that, with FBT, Cmax does not need to be reached for onset of efficacy. The pharmacokinetics of FBT has been assessed in numerous studies to date.18 19 22 23 24 25 26 27 29 This article presents a consolidated analysis of the pharmacokinetic profile of FBT based on pooled data from nine pharmacokinetic studies.

View all citing articles on Scopus
*

This work was previously published in abstract form: Darwish M, Messina J, Tempero K Relative bioavailability and dose proportionality of a novel effervescent form of fentanyl in healthy volunteers. Anesthesiology. 2005;103:A790. Available at: http://www.asabstracts.com/strands/asaabstracts/abstract.htm; jsessionid=0E021F123BAA6313802B30E8044FB145?year=2005&index=6&absnum=1066.

View full text